Company Overview
Context Therapeutics Inc. operates as a biopharmaceutical company dedicated to the development of therapeutic products specifically designed for the treatment of solid tumors. The company's primary focus centers on its lead program candidate, CTIM-76, which functions as an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody engineered to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. Within the broader healthcare sector, the entity functions within the biotechnology industry, a field characterized by high research and development costs and significant regulatory hurdles before products reach market. The company currently maintains a market capitalization of $245.32M, while annual revenue and employee count figures are not disclosed in the available financial data. These valuation metrics, particularly the market cap of $245.32M, indicate that Context Therapeutics is a mid-cap entity operating within a niche therapeutic area, reflecting a stage where value is derived primarily from pipeline potential rather than established commercial revenue streams.
Financial Health
The financial statements for Context Therapeutics Inc. report revenue of N/A for the trailing twelve months, accompanied by a net income of $-36,123,616 and an EBITDA of $-39,686,380. The substantial gap between the reported revenue of N/A and the significant net loss of $-36,123,616 reveals a cost structure where operating expenses, likely dominated by research, development, and clinical trial costs, far exceed current income generation capabilities. The company reports a free cash flow of $-20,457,296, which indicates that current cash outflows for capital expenditures and working capital requirements exceed cash inflows, a typical characteristic for biotechnology firms in development stages that must prioritize R&D investment over immediate profitability. Margin analysis shows a gross margin of 0.0%, an operating margin of 0.0%, and a profit margin of 0.0%, indicating that the company has not yet achieved profitability at any level, with gross and operating margins at zero suggesting that revenue, where recognized, does not cover the direct costs of goods sold or operating expenses respectively. Regarding liquidity and leverage, the company holds $66.00M in cash against total debt of $112,064, resulting in a debt-to-equity ratio of 0.18, which suggests a balance sheet that is relatively conservative with minimal leverage despite the negative earnings. The current ratio stands at 8.52, a figure that indicates strong short-term liquidity, as the company possesses more than eight times the current assets necessary to cover its short-term liabilities. Return on equity is reported at -46.4% and return on assets at -29.8%, metrics that reveal that management effectiveness in generating returns from shareholder capital and total assets is currently negative, consistent with a pre-revenue biotechnology company burning cash to advance its clinical programs.
Valuation Assessment
Valuation metrics for Context Therapeutics Inc. include a trailing P/E ratio of N/A and a forward P/E of -5.77, a discrepancy that implies the market is pricing the stock based on future expectations of earnings turnaround rather than current profitability. The price-to-book ratio is listed at 4.06, indicating that the market values the company at a significant premium over its net asset value, a common valuation multiple for biotechnology firms where intellectual property and pipeline assets are not fully captured on the balance sheet. Alternative valuation metrics such as price-to-sales, which is N/A, and an EV/EBITDA of -4.52 suggest that traditional valuation models are less applicable, with the negative EV/EBITDA reflecting the company's negative earnings before interest, taxes, depreciation, and amortization. The stock's price volatility is framed by a 52-week high of $3.62 and a 52-week low of $0.49, placing the current trading price within a wide historical range that reflects the speculative nature of the asset class. The beta value is listed as N/A, meaning that the company's price volatility relative to the broader market cannot be quantified using this specific historical metric from the available data.
Growth & Income
Growth metrics for Context Therapeutics Inc. show revenue growth (YoY) of N/A and earnings growth (YoY) of N/A, precluding a direct comparison of earnings versus revenue growth rates in the current reporting period. As a non-dividend payer, the company does not distribute a dividend yield or maintain a payout ratio, effectively allocating all available resources toward reinvesting earnings into growth initiatives such as clinical trials and drug development rather than shareholder distributions. This strategy of reinvestment rather than dividend distribution is standard for biotechnology companies in the early to mid-development phases, where capital preservation and pipeline advancement are prioritized over income generation for investors. The overall growth and income profile for Context Therapeutics is defined by a reliance on future commercialization of its solid tumor treatment candidates rather than current earnings growth or dividend income.